May 23, 2019
1 min read

HTX-011 significantly reduced opioid use for 72 hours after bunionectomy of the first metatarsal

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

According to recently published results, HTX-011 significantly reduced postoperative pain through 72 hours after a primary unilateral, distal, first metatarsal bunionectomy and significantly reduced opioid use. In addition, the treatment had a higher proportion of opioid-free patients compared with saline placebo and bupivacaine hydrochloride groups.

In EPOCH I, a randomized, double-blind placebo-controlled and active-controlled phase 3 trial, researchers assigned 412 patients who underwent a primary unilateral, distal, first metatarsal bunionectomy to receive a single dose of HTX-011 (bupivacaine and meloxicam in Biochronomer [AP Pharma] polymer technology), immediate-release bupivacaine hydrochloride (HCI) or saline placebo. Assessments were completed after 72 hours and patients were discharged. Follow-up assessments were performed at day 10, 28 and 42. Patients kept a daily diary and recorded whether they took opioids.

The mean area under the curve of the numeric rating scale (NRS) of pain intensity scores through 72 hours (AUC0-72) for the HTX-011 vs. the saline placebo group was the primary endpoint. Other endpoints included the AUC0-72 of the NRS pain intensity scores for HTX-011 vs. the bupivacaine HCl group, mean total postoperative opioid consumption through 72 hours for HX-011 vs. bupivacaine HCI and saline placebo groups and the proportion of patients who were opioid free through 72 hours for HTX-011 compared with bupivacaine HCl.

HTX-011 showed statistically significant results and a clinically relevant benefit for the primary endpoint and secondary endpoints. Investigators noted through 72 hours, HTX-011 showed superior and sustained pain reduction and significantly decreased opioid consumption. HTX-011 also resulted in significantly more opioid-free patients vs. the saline placebo and bupivacaine HCI groups.

All treatment groups had similar safety results. There were fewer opioid-related adverse events in patients who received HTX-011. – by Monica Jaramillo

Disclosures: Viscusi reports he receives research grants from Pacira and Durect; and receives consulting fees from AcelRx, Avenue, Cara, Concentric, Heron Therapeutics, Innacoll, Mallinckrodt, Merck, Neumentum, Pacira, Pfizer, Recro, Salix and Trevena. Please see the full study for a list of all other authors’ relevant financial disclosures.